Fig. 4: Treatment with AA15V LNP-sSE-SCTs enhances spike-specific T cell-mediated killing of cancer cells.
From: LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment
a Screening of AA LNPs in B16F10 cells. b Construction of saRNA encoding MHC I single-chain trimer (SCT) containing spike epitopes. E spike epitope, TM transmembrane domain. Created in BioRender. Xue, Y. (2025) https://BioRender.com/k91i086. c Dynamic expression of H-2Kb+β2m+ in B16F10 cells. d Expression of OVA-H-2Kb+ in B16F10 cells after a single i.t. injection of AA15V LNP-sOP-SCTs. OP, OVA257-264 peptide (SIINFEKL). e Percentage of apoptotic B16F10 cells in the T cell-mediated killing assay. f Percentage of dead B16F10 cells in the T cell-mediated killing assay. g, h Spike epitope-specific activation of CD4+ T cells (g) and CD8+ T cells (h) isolated from B16F10 tumors in mice vaccinated with AA2 LNP-spike mRNA. CE control epitope, SE spike epitope. Data in (a) and (c) are from n = 3 biologically independent samples. Data in (d) are from n = 4 biologically independent samples. Data in (e–h) are from n = 5 biologically independent samples. Data are presented as mean ± SD. Statistical significance in (a, c) and (e, f) was determined by one-way ANOVA followed by Dunnett’s multiple comparison test. Statistical significance in (d) and (g, h) was determined by the two-tailed Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
